Status: Not yet recruiting
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1195E CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Nov 18, 2025Locations: 1
Eligibility criteria
R/R B-NHL Inclusion Criteria： [+17]
R/R B-NHL Exclusion Criteria： [+37]